Invasive Breast Cancer Risk

FDA Approves Evista To Reduce Invasive Breast Cancer Risk In Postmenopausal Women With Osteoporosis

Editor's Choice
Main Category: Breast Cancer

Evista (raloxifene HCl), a drug aimed at reducing invasive breast cancer risk for both postmenopausal women with osteoporosis and postmenopausal women with a invasive breast cancer risk has been approved by the US Food and Drug Administration (FDA) for both groups of women ...

FDA Approves Evista To Reduce Invasive Breast Cancer Risk In Postmenopausal Women With Osteoporosis